MX2021007324A - Terapia oral con acido 6,8-bis-benciltio-octanoico. - Google Patents
Terapia oral con acido 6,8-bis-benciltio-octanoico.Info
- Publication number
- MX2021007324A MX2021007324A MX2021007324A MX2021007324A MX2021007324A MX 2021007324 A MX2021007324 A MX 2021007324A MX 2021007324 A MX2021007324 A MX 2021007324A MX 2021007324 A MX2021007324 A MX 2021007324A MX 2021007324 A MX2021007324 A MX 2021007324A
- Authority
- MX
- Mexico
- Prior art keywords
- benzylthio
- bis
- octanoic acid
- oral therapy
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención proporciona métodos y composiciones para tratar una enfermedad o trastorno mediante la administración oral a un paciente que lo necesita de ácido 6,8-bis-benciltio-octanoico o una sal aceptable para uso farmacéutico del mismo, opcionalmente en combinación con un segundo agente terapéutico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862782938P | 2018-12-20 | 2018-12-20 | |
US201962834478P | 2019-04-16 | 2019-04-16 | |
PCT/US2019/067763 WO2020132401A1 (en) | 2018-12-20 | 2019-12-20 | Oral therapy using 6,8-bis-benzylthio-octanoic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021007324A true MX2021007324A (es) | 2021-08-16 |
Family
ID=71101630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021007324A MX2021007324A (es) | 2018-12-20 | 2019-12-20 | Terapia oral con acido 6,8-bis-benciltio-octanoico. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220040133A1 (es) |
EP (1) | EP3897606A4 (es) |
JP (1) | JP2022514084A (es) |
KR (1) | KR20210105913A (es) |
CN (1) | CN113543779A (es) |
AU (1) | AU2019405976A1 (es) |
CA (1) | CA3121645A1 (es) |
IL (1) | IL283609A (es) |
MX (1) | MX2021007324A (es) |
TW (1) | TW202038930A (es) |
WO (1) | WO2020132401A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022120055A1 (en) * | 2020-12-03 | 2022-06-09 | New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery | Methods for treating autoimmune diseases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263653B2 (en) * | 2007-04-18 | 2012-09-11 | Cornerstone Pharmaceuticals, Inc. | Pharmaceutical formulations containing lipoic acid derivatives |
CA2717511A1 (en) * | 2008-03-04 | 2009-09-11 | Robert Shorr | Modulation of enzymatic structure, activity, and/or expression level |
WO2011143590A1 (en) * | 2010-05-14 | 2011-11-17 | Cornerstone Pharmaceuticals, Inc. | Combination therapy compositions and methods using lipoic acid derivatives and an anti-proliferation agent |
EP3735968A1 (en) * | 2017-03-20 | 2020-11-11 | Indiana University Research & Technology Corporation | Use of ape1/ref-1 inhibitors in combination therapies for treatment of cancer |
US20190110993A1 (en) * | 2017-09-12 | 2019-04-18 | Raj Selvaraj | Solid Nanoparticle Formulation of Water Insoluble Pharmaceutical Substances with Reduced Ostwald Ripening |
WO2019204251A1 (en) * | 2018-04-16 | 2019-10-24 | Rafael Pharmaceuticals, Inc. | Therapeutic methods and compositions for treating prostate cancer using 6,8-bis-benzylthio-octanoic acid |
-
2019
- 2019-12-20 US US17/414,404 patent/US20220040133A1/en active Pending
- 2019-12-20 EP EP19898742.2A patent/EP3897606A4/en active Pending
- 2019-12-20 MX MX2021007324A patent/MX2021007324A/es unknown
- 2019-12-20 AU AU2019405976A patent/AU2019405976A1/en active Pending
- 2019-12-20 CN CN201980084168.6A patent/CN113543779A/zh active Pending
- 2019-12-20 KR KR1020217019808A patent/KR20210105913A/ko unknown
- 2019-12-20 TW TW108147079A patent/TW202038930A/zh unknown
- 2019-12-20 CA CA3121645A patent/CA3121645A1/en active Pending
- 2019-12-20 JP JP2021535568A patent/JP2022514084A/ja active Pending
- 2019-12-20 WO PCT/US2019/067763 patent/WO2020132401A1/en unknown
-
2021
- 2021-06-01 IL IL283609A patent/IL283609A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN113543779A (zh) | 2021-10-22 |
JP2022514084A (ja) | 2022-02-09 |
US20220040133A1 (en) | 2022-02-10 |
AU2019405976A1 (en) | 2021-06-24 |
IL283609A (en) | 2021-07-29 |
EP3897606A1 (en) | 2021-10-27 |
KR20210105913A (ko) | 2021-08-27 |
EP3897606A4 (en) | 2022-08-31 |
WO2020132401A1 (en) | 2020-06-25 |
TW202038930A (zh) | 2020-11-01 |
CA3121645A1 (en) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
EP4272818A3 (en) | Thrombolytic agent for the treatment of thromboembolism | |
PH12020551425A1 (en) | Rimegepant for cgrp related disorders | |
MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
MX2019012884A (es) | Terapia de combinacion. | |
PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
EP4324521A3 (en) | Treatment of fabry disease in ert-naive and ert-experienced patients | |
AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
MX2021002321A (es) | Nuevos metodos. | |
MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
PH12021550047A1 (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | |
WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
MX2021003681A (es) | Composiciones y metodos para el tratamiento de desordenes inflamatorios. | |
MX2021002322A (es) | Nuevos metodos. | |
MX2022000143A (es) | Metodos novedosos. | |
CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. | |
PH12021550218A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
MX2021011269A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina. | |
MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. |